Search
All Clinical Trials
A listing of 23153 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
13 - 24 of 23153
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Recruiting
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Infirmary Cancer Care ( Site 0001), Mobile, Alabama +209 locations
Conditions: Triple-Negative Breast Cancer
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults
Recruiting
The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
04/24/2025
Locations: University of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland +1 locations
Conditions: Escherichia Infection
Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
Recruiting
Background:
Researchers want see if three new HIV (human immunodeficiency virus) vaccines are safe. Two vaccines are carried by live adenoviruses, which are natural and typically cause cold symptoms or an eye infection. Researchers want to see if all the vaccines help fight HIV and if the adenoviruses are contagious.
Objectives:
To test the safety and effects of three new HIV vaccines.
Eligibility:
Healthy adults 18 49 years old (vaccinees)
Their household and intimate contacts 18 65 years... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy Volunteer
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Recruiting
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: Institute for Female Pelvic Medicine, North Wales, Pennsylvania +4 locations
Conditions: Stress Urinary Incontinence
Promoting Alcohol Treatment Engagement Post-hospitalization
Recruiting
This study is a 3-arm randomized clinical trial to evaluate the effectiveness of hospital-initiated Alcohol Use Disorder treatment, involving a Brief Negotiated Interview (with referral and telephone booster) alone, BNI+facilitated provision of MAUD, BNI+facilitated provision of MAUD+CBT4CBT on AUD treatment engagement, alcohol use and healthcare utilization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Alcohol Use Disorder
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Recruiting
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Urology Centers Of Alabama, Homewood, Alabama +90 locations
Conditions: Metastatic Castrate-sensitive Prostate Cancer
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Recruiting
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/24/2025
Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona +53 locations
Conditions: Obesity, Overweight
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
This is a multicenter study which will enroll approximately 75 subjects
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/24/2025
Locations: Shiley Eye Institute, San Diego, California +12 locations
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Tirzepatide for Obesity and Meth Use Disorder
Recruiting
This is an open-label pilot study to evaluate the feasibility and preliminary efficacy of using tirzepatide when prescribed for its United States (US) Food and Drug Administration (FDA)-approved weight-related indication in individuals with comorbid methamphetamine use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Obesity, Methamphetamine Use Disorder
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Recruiting
Background:
For children with gigantism, too much growth hormone (GH) in the body causes abnormal growth and many other problems. Current treatments often don t work; no medical treatment is approved by FDA. Researchers want to see if the drug pegvisomant can help.
Objective:
To test the role of pegvisomant in children and adolescents with gigantism.
Eligibility:
People ages 2-18 with GH excess for whom usual treatments have not worked or who are not eliginle for them
Design:
Participants... Read More
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
04/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pituitary Disease
GYNEMESH PS Mesh Post Marketing Clinical Follow-Up Study
Recruiting
The objective of this retrospective and prospective, single-arm, observational, multicenter, post-market study is to evaluate outcomes in women who underwent surgery for vaginal or uterine prolapse with a GYNEMESH PS Mesh.
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
04/24/2025
Locations: Institute for Female Pelvic Medicine, North Wales, Pennsylvania +2 locations
Conditions: Pelvic Organ Prolapse
Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)
Recruiting
This is a multicenter trial to establish the efficacy of cooling and the optimal duration of induced hypothermia for neuroprotection in pediatric comatose survivors of cardiac arrest.
The study team hypothesizes that longer durations of cooling may improve either the proportion of children that attain a good neurobehavioral recovery or may result in better recovery among the proportion already categorized as having a good outcome.
Gender:
ALL
Ages:
Between 2 days and 17 years
Trial Updated:
04/24/2025
Locations: University of Alabama at Birmingham / Children's of Alabama, Birmingham, Alabama +52 locations
Conditions: Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
13 - 24 of 23153